Technology evaluation: HIVAC-1e.

R Zheng

Home/Archive/PubMed

PubMed · 11249677

Technology evaluation: HIVAC-1e.

R Zheng

View original source ↗Export metadata ↓

Abstract

Bristol-Myers Squibb is developing a vaccine, HIVAC-1e, comprised of a recombinant vaccinia virus expressing the HIV-1 gp160 envelope glycoprotein. The vaccine has potential for the treatment of HIV and other viral infections and has entered phase I trials [135333]. In an initial phase I trial, 11 vaccinia-naïve volunteers were vaccinated with HIVAC-1e, followed by a booster with baculovirus-derived gp160 (VaxSyn). Two weeks after boosting, all 11 volunteers developed HIV-1 specific IgG, with titers of 1:40 to 1:1280 [195287]. Using the same strategy in 29 vaccinia-naïve volunteers, priming with HIVAC-1e was demonstrated as a key determinant of the epitope specificity and magnitude of antibody responses to gp160 [195278].

Explore related subjects

AIDS Vaccines Animals Biotechnology HIV Envelope Protein gp160 HIV Infections Humans Mice Safety Vaccines, DNA Vaccinia virus Clinical Trial Clinical Trial, Phase I Evaluation Study Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

R Zheng. 1999. Technology evaluation: HIVAC-1e.. https://pubmed.ncbi.nlm.nih.gov/11249677/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2025

Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-like antibodies.

Antibodies belonging to the VRC01-class display broad and potent neutralizing activities and have been isolated from several people living with HIV (PLWH). A member of that class, monoclonal antibody VRC01, was shown to reduce HIV-acquisition in two phase 2b efficacy trials. VRC01-class antibodies are therefore expected to be one component of an effective HIV-1 vaccine elicited response. In contrast to the VRC01-class antibodies that are highly mutated, their unmutated forms do not engage HIV-1 envelope (Env) and do not display neutralizing activities. Hence, specifically modified Env-derived proteins have been designed to engage the unmutated forms of VRC01-class antibodies, and to activate the corresponding naïve B cells. Selected heterologous Env must then be used as boost immunogens to guide the proper maturation of these elicited VRC01-class antibodies. Here we examined whether and how the valency of the prime and boost immunogens influences VRC01-class antibody-maturation. Our findings indicate that, indeed the valency of the immunogen affects the maturation of elicited antibody responses by preferentially selecting VRC01-like antibodies that have accumulated somatic mutations present in broadly neutralizing VRC01-class antibodies isolated from PLWH. As a result, antibodies isolated from animals immunized with the higher valency immunogens display broader Env cross-binding properties and improved neutralizing potentials than those isolated from animals immunized with the lower valency immunogens. Our results are relevant to current and upcoming phase 1 clinical trials that evaluate the ability of novel immunogens aiming to elicit cross-reactive VRC01-class antibody responses.

AIDS Vaccines↗

PubMed2015

New approaches to HIV vaccine development.

Development of a safe and effective vaccine for HIV is a major global priority. However, to date, efforts to design an HIV vaccine with methods used for development of other successful viral vaccines have not succeeded due to HIV diversity, HIV integration into the host genome, and ability of HIV to consistently evade anti-viral immune responses. Recent success in isolation of potent broadly neutralizing antibodies (bnAbs), in discovery of mechanisms of bnAb induction, and in discovery of atypical mechanisms of CD8T cell killing of HIV-infected cells, have opened new avenues for strategies for HIV vaccine design.

AIDS Vaccines↗

PubMed2005

Measuring HIV vaccine efficacy.

Some HIV vaccine candidates have a potential VE I (vaccine efficacy for infectiousness) type effect, which tends to reduce the viral load and may reduce infectiousness of an infected individual. In general, the efficacy of this kind of vaccine is very difficult to assess because it requires information on contacts of vaccinated infected individuals, and current methods to estimate VE I rely on the time elapsed between infections of an individual and his/her sexual partner, thus making infection of the sexual partner necessary to assess the efficacy. To avoid behavioural changes that may affect the estimates, HIV status is kept undisclosed to participants, which raises many ethical questions. Here we present a method that allows immediate notification of HIV status to both members of a couple, reducing the risk of infection when one of them has not been infected and allowing immediate medical treatment. The method allows for estimation of any VE I and VE S (vaccine efficacy for susceptibility) effect, and it is robust to the most common situations found in these type of studies, namely: differential risk of participants, staggered enrollment and small sample sizes.

AIDS Vaccines↗